Navigation Links
Diverse Coalition of Purchasers Respond to BIO CEO Fly-In: There is Another Side to The Story

Patients Need A Biogenerics Pathway that DOESN'T Keep Them Waiting

WASHINGTON, April 16 /PRNewswire-USNewswire/ -- With dozens of biotech and drug company CEOs flying to Capitol Hill to meet with members of Congress, The Coalition for a Competitive Pharmaceutical Market (CCPM) today released a new ad urging members to keep the best interests of patients in mind as they consider legislation to create a workable approval pathway for safe, effective and affordable biogeneric medicines.

The ad, "What If Patients Had Wings?," states that meaningful biogenerics legislation should ensure that patients have access to life saving biogeneric medicines sooner rather than later. Such legislation must strike the balance of fostering innovation without harming patient access through excessive and unprecedented market exclusivity which simply extends brand monopolies and stifles competition. A bill that does not achieve this objective will be an empty promise to patients.

A broad coalition of patients, seniors, consumers, businesses, labor, pharmacists, health plans, pharmacy benefit managers, and generics supplemented this effort by sending a letter to House Energy and Commerce Committee Chairman John Dingell and Ranking Member Joe Barton reiterating its principles for workable and balanced biogenerics legislation that:

1. Empowers the FDA to use its expertise to determine on a case by case

basis what scientific data they need to approve comparable and

interchangeable products.

2. Does not include administrative barriers that impede FDA's ability to

approve safe and effective biogenerics.

3. Provides a clear framework for interchangeability that is immediately

operative and does not require additional congressional action.

4. Ensures predictability for when scientifically-proven, safe and

effective biogenerics can enter the marketplace.

5. Provides a clear and timely resolution to patent disputes and

prohibits frivolous suits that restrict access to biogenerics and

delay competition in the marketplace.

6. Creates a balanced process that encourages innovation by both brand

and generic companies and expands access to prescription medications

for consumers.

7. Does not create a system of endless monopoly pricing and no

opportunity for competition to enter the marketplace.

The following is the text of the latest CCPM ad:

What If Patients Had Wings?

Executives from the multi-billion dollar pharmaceutical and biotech

industry are descending on Congress...flying to Washington to make sure

their monopolies are protected.

Meanwhile countless Americans are struggling to pay for high-priced

biopharmaceutical medicines.

These patients can't fly to Washington on their own, but they are making

their voices heard.

Numerous organizations representing patients, seniors, consumers, labor,

and businesses support legislation to establish a workable approval

pathway for biogenerics.

Americans need balanced legislation that fosters innovation without

excessive market exclusivity which does nothing more than extend

monopolies, stifle competition and keep patients waiting for affordable


BIO and PhRMA say that want a biogenerics pathway, but their policy is an

empty promise to patients.

CCPM supports public policies that facilitate timely access to affordable pharmaceuticals. Visit for more information and a list of CCPM members.

Contact: Katie Braden Huffard, 202-255-5216;

Andrea Hofelich, 703-647-2495; Charles Cote, 202-207-3605

SOURCE The Coalition for a Competitive Pharmaceutical Market(CCPM)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
2. FrontPath Health Coalition To Lead Community-wide Group in Pilot Program
3. Coalition for a Competitive Pharmaceutical Market Launches New Print Ad Campaign Highlighting Need for Meaningful Biogenerics Legislation
4. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
5. Agendia Joins the Personalized Medicine Coalition (PMC)
6. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
7. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
8. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
9. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
10. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
11. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
Breaking Biology News(10 mins):